Lon Kreger has been appointed as Stimera's new CEO. Stimera, formerly BioAge, has appointed Lon E. Kreger as its new CEO. This change marks a key step as the company shifts from testing and early sales to broader global growth. Stimera creates special fertilizers called molecular foliar fertilizers that help plants absorb nutrients quickly and boost growth. Its main product, Nitro-Gro, changes nutrient molecules so they enter leaves faster, speeding up plant metabolism and increasing yields. The company claims its products can improve crop yields by about 30 percent, shorten growing cycles by two weeks, and provide up to five times return on investment in the same season. Kreger said, "We focus on delivering products that produce real results for growers - helping them get better yields, efficiency, and quality." Stimera is moving from regional development to global sales, working with agricultural stores, distributors, and partners to reach more growers. Kreger added, "Our technology solves real problems by helping growers achieve more consistent yields and better returns." The technology was created by Reuben Rampersad, the founder and president, who has a Ph.D. in plant physiology. He focused on developing solutions that improve nutrient efficiency and support large-scale farming worldwide. Rampersad will continue leading product development and innovation. With Kreger managing global sales and Rampersad focusing on product creation, Stimera plans to expand trials, build partnerships, and grow its new category of fertilizers. The company aims to increase adoption through branded products, private label programs, and collaborations with manufacturers.

BioAge Labs to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference. EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) - BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging. Contacts PR: Chris Patil, [email protected] IR: Dov Goldstein, [email protected] Partnering: [email protected] Web: https://bioagelabs.com Company Profile BioAge Labs, Inc. Industry: Pharmaceuticals & Biotechnology Recommended reading. Explore. February 22, 2026 08:00 ET February 21, 2026 19:51 ET February 21, 2026 12:04 ET February 22, 2026 10:00 ET February 22, 2026 09:00 ET February 22, 2026 08:00 ET February 21, 2026 19:51 ET February 21, 2026 12:04 ET February 22, 2026 10:00 ET February 22, 2026 09:00 ET February 22, 2026 08:00 ET February 21, 2026 19:51 ET February 21, 2026 12:04 ET